Talaporfin

From Self-sufficiency
Revision as of 16:52, 30 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s): antineoplastic-drug-stub)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Talaporfin
File:Talaporfin.png
Systematic (IUPAC) name
N-{[(2S,3S)-7-carboxy-3-(2-carboxyethyl)-12-ethyl-2,8,13,18-tetramethyl-17-vinyl-2,3-dihydroporphyrin-5-yl]acetyl}-L-aspartic acid
Clinical data
Routes of
administration
IV
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
CAS Number 110230-98-3
220201-34-3 (sodium salt)
ATC code none
PubChem CID 5486799
Chemical data
Formula C38H41N5O9
Molar mass 711.76 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorine e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT).

It absorbs red light at 664nm normally provided by a laser tuned to this wavelength.[1]

It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



  1. http://journals.lww.com/jto/Fulltext/2006/06000/Photodynamic_Therapy__PDT__for_Lung_Cancers.18.aspx "Photodynamic Therapy (PDT) for Lung Cancers" 2006
  2. http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7229 "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer" 2006